Baixin An-B(02185.HK)Net loss of 68.4 million yuan in 2025, a decrease of 26.7% year-on-year

NightAirdropper · 2026-03-27T19:39:52+00:00

Baixin'an-B achieved revenue of 44.93 million yuan in 2025, with a net loss of 68.4 million yuan, a 26.7% decrease year-over-year. The Iberis® RDN system was approved for hypertension treatment, recording 44.9 million in revenue in 2025, completing its first surgery in Europe, and launching ischemic heart disease trials in Japan.

NightAirdropper

2026-03-27 19:39:52

Abstract generation in progress

Gelonghui March 27丨 Baixin An-B (02185.HK) released its performance for the fiscal year 2025. As of the fiscal year ending December 31, 2025, the group’s revenue was 44.93 million yuan. The group recorded a net loss of approximately 68.4 million yuan, a decrease of 26.7% compared to 2024. The basic and diluted loss per share for 2025 was 0.29 yuan.

On February 26, 2025, the Iberis® RDN system was approved by the National Medical Products Administration for the treatment of resistant hypertension and hypertensive patients with drug intolerance. Due to the global rollout of the Iberis® RDN system, the group recorded revenue of 449 million yuan for the fiscal year ending December 31, 2025 (2024: none). In February 2025, the Iberis® RDN system completed its first commercial surgery in Europe. On March 27, 2025, the company successfully enrolled its first patient in Tokyo for the SAKURASCB trial targeting ischemic heart disease.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.